Molecular Partners CEO, Patrick Amstutz, Elected President of the Swiss Biotech Association
03 mai 2022 12h00 HE
|
Molecular Partners
BASEL, Switzerland and ZURICH-SCHLIEREN, Switzerland, May 03, 2022 (GLOBE NEWSWIRE) -- The Swiss Biotech Association and Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech...
Molecular Partners to Regain Global Rights for MP0310 from Amgen
26 avr. 2022 16h05 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
Molecular Partners Provides Update on Ensovibep Following Novartis Quarterly Earnings Call
26 avr. 2022 14h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland & CONCORD, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
Molecular Partners Announces Presentation of the EMPATHY Study of Ensovibep for the Treatment of COVID-19 at ECCMID 2022
23 avr. 2022 01h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 23, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners to Present at Kempen Life Sciences Investor Conference
13 avr. 2022 12h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
13 avr. 2022 09h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Announces Publication of Preclinical Data from CD40 Therapeutic Candidate MP0317 in Cancer Immunology Research
24 mars 2022 02h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Publishes Invitation to Annual General Meeting 2022
17 mars 2022 01h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021
15 mars 2022 16h30 HE
|
Molecular Partners
Research & Development Highlights: In January of 2022, announced positive topline results from Phase 2 EMPATHY clinical trial of ensovibep for the treatment of non-hospitalized COVID-19 patients,...
Molecular Partners to Present at Upcoming Healthcare Investor Conferences
25 févr. 2022 16h30 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...